NetworkNewsBreaks – INmune Bio, Inc.’s (NASDAQ
Post# of 33
(Total Views: 225)
Posted On: 10/17/2019 3:50:53 PM
NetworkNewsBreaks – INmune Bio, Inc.’s (NASDAQ: INMB) Lead Compound XPro1595 Data to be Presented at the Society for Neuroscience’s Annual Meeting
INmune Bio, Inc. (NASDAQ: INMB) today announced a poster presentation related to its program in Alzheimer’s disease at the upcoming Society for Neuroscience (“SfN”) 49th Annual Meeting to be held at McCormick Place in Chicago from Oct. 19–23, 2019. The company also announced that its poster was selected for presentation during the meeting’s press conference. The data from studies involving the use of INmune Bio’s XPro1595, as presented in a poster by Malú Tansey, Ph.D., Professor of Neuroscience and Director of the Center for Translational Research in Neurodegenerative Disease at the University of Florida College of Medicine, demonstrate the critical role of the immune system on an individual’s genetic risk in the context of environmental exposures, such as a diet high in fat and sugar, for neurodegenerative diseases such as Alzheimer’s. “It’s become clear that neurological disorders can arise from or be exacerbated by innate immune dysfunction and chronic inflammation resulting from both genetic and environmental factors such as diet,” Dr. Tansey said in the news release. “Harnessing the power of the immune system could potentially delay or perhaps even prevent some of these neurological disorders. Our results provide a compelling rationale for moving forward with a clinical trial in early Alzheimer’s disease patients.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
INmune Bio, Inc. (NASDAQ: INMB) today announced a poster presentation related to its program in Alzheimer’s disease at the upcoming Society for Neuroscience (“SfN”) 49th Annual Meeting to be held at McCormick Place in Chicago from Oct. 19–23, 2019. The company also announced that its poster was selected for presentation during the meeting’s press conference. The data from studies involving the use of INmune Bio’s XPro1595, as presented in a poster by Malú Tansey, Ph.D., Professor of Neuroscience and Director of the Center for Translational Research in Neurodegenerative Disease at the University of Florida College of Medicine, demonstrate the critical role of the immune system on an individual’s genetic risk in the context of environmental exposures, such as a diet high in fat and sugar, for neurodegenerative diseases such as Alzheimer’s. “It’s become clear that neurological disorders can arise from or be exacerbated by innate immune dysfunction and chronic inflammation resulting from both genetic and environmental factors such as diet,” Dr. Tansey said in the news release. “Harnessing the power of the immune system could potentially delay or perhaps even prevent some of these neurological disorders. Our results provide a compelling rationale for moving forward with a clinical trial in early Alzheimer’s disease patients.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)